CLDI (Calidi Biotherapeutics, Inc.) Stock Analysis - Analyst Ratings

Calidi Biotherapeutics, Inc. (CLDI) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDI trades at $0.17 with a market cap of $2.79M and a P/E ratio of -0.03. CLDI moved -8.04% today. Year to date, CLDI is -85.53%; over the trailing twelve months it is -96.84%. Its 52-week range spans $0.16 to $46.68. Rallies surfaces CLDI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate CLDI?

The average price target is $0.00.

CLDI Key Metrics

Key financial metrics for CLDI
MetricValue
Price$0.17
Market Cap$2.79M
P/E Ratio-0.03
EPS$-5.95
Dividend Yield0.00%
52-Week High$46.68
52-Week Low$0.16
Volume1.70M
Avg Volume0
Revenue (TTM)$0
Net Income$-20.06M
Gross Margin0.00%

CLDI Analyst Consensus

CLDI analyst coverage data. Average price target: $0.00.

Latest CLDI News

Recent CLDI Insider Trades

  • Camaisa Allan sold 850 (~$1.24K) on Dec 12, 2025.
  • Schoeneck James A bought 75.00K (~$150.00K) on Aug 21, 2025.
  • Poma Eric E bought 25.00K (~$50.00K) on Aug 21, 2025.

Common questions about CLDI

What do analysts rate CLDI?
The average price target is $0.00.
Does Rallies show CLDI price targets?
Yes. Rallies tracks CLDI analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is CLDI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.
CLDI

CLDI